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Purpose: To study changes in choroidal thickness with ranibizumab treatment for choroidal 
neovascularization (CNV).
Design: Prospective case series.
Methods: This prospective study consisted of 60 CNV-affected eyes of 60 patients treated 
with intravitreal injections of ranibizumab using an on-demand protocol after an initial loading 
phase. The eyes studied included 20 with age-related macular degeneration (AMD), 20 with 
polypoidal choroidal vasculopathy (PCV), and 20 with myopic CNV . In the eyes with AMD and 
PCV , choroidal thickness at the fovea was measured with optical coherence tomography using 
enhanced depth imaging. In eyes with myopic CNV , the choroidal thickness was measured using 
standard optical coherence tomography without the enhanced depth imaging technique.
Results: With ranibizumab treatment, central retinal thickness decreased significantly 
(P , 0.001) and visual acuity improved significantly (P , 0.001). However, central choroi-
dal thickness (167.2 ± 108.3 µm) showed no significant change at 1 month after the loading 
phase (165.2 ± 107.8 µm, P = 0.120) or at final examination (164.8 ± 107.7 µm, P = 0.115). 
At baseline, central retinal thickness in eyes with AMD was significantly greater that those 
with PCV (P = 0.005) or high myopia (P = 0.029). However, central choroidal thickness in 
eyes with myopic CNV was significantly thinner than in eyes with AMD (P , 0.001) or PCV 
(P , 0.001). In each type of disease, there was no significant change in central choroidal thick-
ness with ranibizumab treatment.
Conclusion: The effect of ranibizumab on the choroidal thickness is minimal, if any.
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Introduction
Ranibizumab, a Fab fragment of a recombinant, humanized, monoclonal antibody, 
blocks all isoforms of vascular endothelial growth factor (VEGF)-A.1 The inhibition 
of VEGF-A reduces the leakage from choroidal neovascularization (CNV) and further 
growth of CNV .2,3 The current standard treatment for exudative age-related macular 
degeneration (AMD) is intravitreal injections of ranibizumab.4 Previous large-scale, 
prospective, randomized studies of eyes with AMD showed dramatic effects of ranibi-
zumab on CNV and subsequent improvement of visual acuity.5,6 However, most patients 
with AMD require frequent injections of ranibizumab to maintain the initial visual 
improvement during the loading phase.7 Mendrinos et al8 recently reported that the 
retinal arteriolar diameter was reduced by 18.5% at 30 days and by 19.1% at 12 months 
after the initiation of ranibizumab treatments for exudative AMD. Because VEGF has 
various physiological effects on eyes, including cell proliferation,9 neuroprotective 
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effects,10 maintenance of the choriocapillaris,11 and increases 
in ocular blood flow,12 long-term inhibition of VEGF may 
adversely affect the eye.13
The choroid is a multifunctional structure with one of the 
highest blood flow rates in the body.14,15 It primarily works 
to support the function and nutrition of the outer retina, 
including photoreceptors and retinal pigment epithelium.15 
Since Spaide et al16 introduced enhanced depth-imaging 
optical coherence tomography (EDI-OCT), which is based 
on spectral-domain OCT technology, many investigators 
have reported on the role of the choroid in the pathogenesis 
of various ocular diseases,17–22 including AMD,23–25 poly-
poidal choroidal vasculopathy (PCV),23,24,26 central serous 
chorioretinopathy,27,28 and myopic CNV .29,30 It has recently 
been suggested that choroidal thinning may be involved in 
the development of CNV associated with AMD and high 
myopia.23,24,31 VEGF works to induce vessel dilation and to 
increase ocular blood flow through a mechanism involving 
increased nitric oxide production.32,33 It is then possible that 
long-term inhibition of VEGF by ranibizumab might cause 
the constriction of the choroidal vessels, leading to further 
thinning of the choroid. Thus far, however, only limited 
information is available on the effects of ranibizumab on 
the choroid. In this prospective study, we performed longi-
tudinal measurements of choroidal thickness before and after 
ranibizumab treatment for CNV associated with AMD, PCV , 
and high myopia to evaluate the possible adverse effects of 
ranibizumab on the choroid.
Patients and methods
This prospective study consisted of 60 eyes of 60 patients 
with CNV treated with intravitreal injections of ranibi-
zumab (Lucentis; Novartis, Bülach, Switzerland). The 
choroidal thickness of the eyes was examined using OCT at 
Kyoto   University Hospital between May 2010 and August 
2011. The underlying pathology of the 60 eyes included 
20   consecutive eyes with AMD, 20 with PCV , and 20 with 
myopic CNV. The inclusion criteria for the study groups 
were (1) symptomatic neovascular lesions beneath the center 
of the fovea, (2) the presence of active exudative features 
involving the macula, (3) treatment by intravitreal injec-
tions of ranibizumab after the initial diagnosis, and (4) OCT 
examination before and after treatments. Exclusion criteria 
were (1) the obscuration of retinal or choroidal images by 
media opacity or thick subfoveal hemorrhage, (2) a history 
of intraocular inflammation, (3) the presence or history of 
other macular abnormalities (eg, idiopathic CNV, retinal 
angiomatous   proliferation, angioid streaks, other secondary 
CNV , or central serous chorioretinopathy), (4) a history of 
previous treatment for CNV , and (5) eyes with a history of 
pars plana vitrectomy or other intraocular surgeries, except 
history of cataract surgery. Subjects with systemic diseases 
or conditions that could affect retinal or choroidal thickness 
were also excluded, such as those with Vogt-Koyanagi-Har-
ada disease, malignant hypertension, or pregnant women.
At  the  initial  visit,  each  patient  underwent  a 
  comprehensive ophthalmologic examination, including 
measurement of   best-corrected visual acuity with a Landolt 
chart;   determination of intraocular pressure; indirect 
  ophthalmoscopy; slit lamp biomicroscopy with a contact 
lens; OCT examination (Spectralis HRA+OCT;   Heidelberg 
Engineering, Heidelberg, Germany); and fluorescein and 
indocyanine green angiography (HRA-2; Heidelberg 
  Engineering). The diagnostic criteria for PCV were based on 
indocyanine green angiography, which showed a branching 
vascular network that terminates in polypoidal swelling. The 
diagnosis of myopic CNV was based on a minimum spheri-
cal equivalent refractive error of more than −6.0 diopters or 
an axial length of more than 26.5 mm, characteristic retinal 
signs of high myopia, and evidence of CNV based on the 
presence of leakage on fluorescein angiography and/or 
intraretinal or subretinal fluid on OCT.
At the loading phase, all eyes with PCV and AMD received 
three successive intravitreal injections of ranibizumab 
at monthly intervals (at baseline and at 1 and 2 months); 
eyes with myopic CNV were treated by a single injection 
of   ranibizumab. After the loading phase, each patient was 
scheduled for an examination each month, at which time they 
underwent a comprehensive ophthalmologic examination. 
Each eye was re-treated by an intravitreal injection of ranibi-
zumab as an on-demand protocol, depending on the presence 
of exudative signs, such as intraretinal edema or subretinal 
fluid on OCT and/or leakage on fluorescein angiography 
during follow-up. Injections of ranibizumab were performed 
under sterile conditions, and prophylactic topical antibiotics 
were applied for 1 week after the injection.
In eyes with AMD and PCV , the choroidal thickness was 
measured using the EDI technique, which was performed by 
placing the OCT instrument close enough to the eye to obtain 
an inverted image. All images were obtained using an eye-
tracking system, and 100 scans were averaged automatically 
to improve the signal-to-noise ratio. The central choroidal 
thickness, defined as the vertical distance between the outer 
surface of the retinal pigment epithelium and the hyperreflec-
tive line of the chorioscleral interface, was measured from the 
horizontal line scan under the center of the fovea. In eyes with 
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myopic CNV, the choroidal thickness was measured with 
standard OCT without the EDI technique, as identification of 
the chorioscleral interface in eyes with high myopia is easy 
and reliable. The central retinal thickness was defined as the 
distance between the inner surface of the neurosensory retina 
and the inner surface of the retinal pigment epithelium under 
the center of the fovea. All measurements were done manu-
ally by a retina specialist, blinded to the study parameters, 
using a built-in caliber OCT machine.
All statistical tests were performed using SPSS   version 
16.0 software (SPSS Inc, Chicago, IL). All values are 
  presented as mean ± standard deviation. For statistical 
  analysis,   best-corrected visual acuity as measured with a 
Landolt chart was converted to a logarithm of the minimal 
angle of   resolution. Initial measurement values between 
the three types of diseases were compared using one-
way analysis of variance with Bonferroni   corrections. 
  Measurements before and after the treatments were 
analyzed by repeated measures analysis of variance, and 
multiple comparisons were done using the Bonferroni 
post-hoc method. A P value of ,0.05 was considered 
statistically significant.
Results
In the current study, 60 eyes of 60 patients (36 men 
and 24 women; age range, 35–90 years; mean age, 
71.1 ± 9.6 years) with subfoveal CNV were treated with 
ranibizumab. Table 1 shows the initial characteristics of the 
study population. Table 2 shows the change in mean visual 
acuity, central retinal thickness, and central choroidal 
thickness before and after treatments with ranibizumab. 
Of the 60 eyes studied, 20 had AMD, 20 had PCV, and 
20 had myopic CNV . The mean follow-up period was 
8.9 ± 3.9 months. The mean refractive error was 1.54 
(± 1.75) diopters (D) (range: −1.75–+3.0 D) in the AMD 
group, −0.56 (± 1.28) (range: −2.75–+2.5 D) in the PCV 
group, and −10.96 (± 3.32) (range: −21.0–−7 D) in the 
myopic CNV group. The mean axial length in eyes with 
myopic CNV was 28.71 ± 1.01 mm. With ranibizumab 
treatment, central retinal thickness decreased significantly 
at 1 month after the loading phase (P , 0.001) and at 
final examination (P , 0.001). In parallel with the reduc-
tion of retinal thickness, visual acuity was significantly 
improved at 1 month after the loading phase (P = 0.005) 
and at final examination (P , 0.001). However, choroidal 
thickness (167.2 ± 108.3 µm) showed no significant change 
at 1 month after the loading phase (165.2 ± 107.8 µm, 
P = 0.120) or at final examination (164.8 ± 107.7 µm, 
P = 0.115) (Table 2).
At baseline, the central retinal thickness in eyes 
with AMD was significantly greater than in eyes with 
PCV (P = 0.005) or myopic CNV (P = 0.029). However, 
  central choroidal thickness in eyes with myopic CNV was 
  significantly lower than in eyes with AMD (P , 0.001) 
or PCV (P , 0.001). Immediately after the initiation 
of   treatment, OCT examination showed reduced exuda-
tive change in eyes with AMD, PCV, and myopic CNV. 
  Retinal thickness was significantly reduced with the 
reduction of serous retinal detachment and macular edema 
 ( Figures 1–3). Figure 4 shows the change in central retinal 
thickness in each group. This reduction in retinal   thickness 
was similar in each type of disease.   However, OCT exami-
nation showed no change in the   choroidal structure with the 
treatments (Figures 1–3). There was no significant change 
in central choroidal thickness with treatment in any of the 
disease types (Figure 4).
Table 1 Characteristics of cohort eyes










Number of eyes 60 20 20 20
Age (years) 71.1 ± 9.6 76.2 ± 6.2 71.7 ± 9.2 65.6 ± 10.3 0.001
Sex (male/female) 36/24 15/5 16/4 5/15 0.001
refractive error (diopters)  
(range)
−2.74 ± 5.97  
(−21.0–+3.0)
1.54 ± 1.75  
(−1.75–+3.0)
−0.56 ± 1.28  
(−2.75–+2.5)
−10.96 ± 3.32  
(−21.0–−7.0)
,0.001
Number of injections  
(range)
3.2 ± 1.4 
(1–7)
3.5 ± 0.9  
(3–6)
3.9 ± 1.4  
(3–7)
2.2 ± 1.3  
(1–5)
,0.001
Follow-up (months) 8.9 ± 3.9 8.4 ± 3.7 8.4 ± 3.3 9.8 ± 4.6 0.422
Visual acuity (logMAr)a 0.45 ± 0.37 0.61 ± 0.41 0.24 ± 0.23 0.49 ± 0.37 0.004
Central retinal thickness (µm) 436.0 ± 198.5 551.0 ± 232.5 361.2 ± 161.4 395.9 ± 143.9 0.004
Central choroidal thickness (µm) 167.2 ± 108.3 217.4 ± 98.6 230.8 ± 68.8 53.6 ± 38.2 ,0.001
Notes: aLogMAr, logarithm of the minimum angle of resolution; bvalues were compared using one-way analysis of variance with Bonferroni corrections.
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of 47 eyes with exudative AMD treated with ranibizumab, 
Sadda et al37 have recently noted that choroidal thickness 
appears to decrease slightly over time in eyes with exudative 
AMD, but that ranibizumab does not appear to accelerate 
this decline. Previously, Margolis and Spaide18 reported that 
subfoveal choroidal thickness decreased by 1.56 µm per year 
in normal subjects. Our patients showed a mean decrease of 
2.4 µm (1.4%) in central choroidal thickness during a mean 
follow-up time of 8.9 months. This decrease in choroidal 
thickness may not be so different from the change seen in 
normal subjects.
More recently, Koizumi et al38 reported that in eyes with 
exudative AMD treated with ranibizumab, mean subfoveal chor-
oidal thickness decreased from 228 µm at baseline to 213 µm 
at 3 months (P = 0.001), 215 µm at 6 months (P = 0.009), and 
213 µm at 12 months (P = 0.015). Although the authors found 
a statistically significant decrease in the foveal choroidal thick-
ness, the mean reduction was only 15 µm. Recently, Ikuno et al39 
reported that the intervisit intraclass correlation coefficient for 
foveal choroidal thickness was 0.893 (95% CI, 0.864–0.916). 
However, because measurement of choroidal thickness has 
high variance due to focal irregularities or indistinctness of 
the chorioscleral border,23,24,40,41 it might be difficult to detect 
minimal changes in thickness practically, even with the EDI-
OCT technique. Based on the current findings and other recent 
reports, the effect of ranibizumab on choroidal thickness is 
estimated to be small, if any.
In contrast to AMD23,24 and high myopia,29,30 previous 
reports showed increased choroidal thickness in PCV .23,24,26 
Table 2 Changes in visual acuity, retinal thickness, and choroidal thickness during ranibizumab treatment
Before treatment After the loading phaseb,c At final examinationc
Visual acuity (logMAr)a
  Total 0.45 ± 0.37 0.33 ± 0.38 (0.005) 0.28 ± 0.34 (,0.001)
  Age-related macular degeneration 0.61 ± 0.41 0.58 ± 0.43 (0.663) 0.45 ± 0.33 (0.030)
  Polypoidal choroidal vasculopathy 0.24 ± 0.23 0.19 ± 0.29 (0.885) 0.12 ± 0.25 (0.046)
  Myopic choroidal neovascularization 0.49 ± 0.37 0.23 ± 0.28 (,0.001) 0.24 ± 0.31 (,0.001)
Central retinal thickness (µm)
  Total 436.0 ± 198.5 262.9 ± 113.8 (,0.001) 256.7 ± 106.0 (,0.001)
  Age-related macular degeneration 551.0 ± 232.5 298.4 ± 156.6 (,0.001) 293.2 ± 147.8 (,0.001)
  Polypoidal choroidal vasculopathy 361.2 ± 161.4 244.7 ± 92.2 (0.008) 236.2 ± 76.1 (0.004)
  Myopic choroidal neovascularization 395.9 ± 143.9 245.7 ± 72.1 (,0.001) 240.8 ± 71.7 (,0.001)
Central choroidal thickness (µm)
  Total 167.2 ± 108.3 165.2 ± 107.8 (0.120) 164.8 ± 107.7 (0.115)
  Age-related macular degeneration 217.4 ± 98.6 214.2 ± 99.2 (0.305) 215.1 ± 98.7 (0.586)
  Polypoidal choroidal vasculopathy 230.8 ± 68.8 228.7 ± 68.0 (0.876) 227.4 ± 67.9 (0.138)
  Myopic choroidal neovascularization 53.6 ± 38.2 52.7 ± 38.5 (1.00) 51.9 ± 38.2 (0.348)
Notes: aLogMAr, logarithm of the minimum angle of resolution; bat the loading phase, all eyes with PCV and AMD received three successive intravitreal injections of 
ranibizumab at monthly intervals (at baseline and at 1 and 2 months); eyes with myopic CNV were treated by a single injection of ranibizumab; cdata were analyzed by 
repeated measures analysis of variance and multiple comparisons were done using the Bonferroni post-hoc method.
Discussion
An increasing number of investigators have studied 
the choroid in association with the pathophysiology of   
various chorioretinal diseases.17–24,29,34,35 With the use of EDI-
OCT, Chung et al23 and Koizumi et al24 separately reported 
foveal choroidal thinning in eyes with exudative AMD. In 
addition, with the use of 3-dimensional OCT at 1060 nm, 
Wood et al36 reported choroidal thinning of the macular area 
in eyes with early AMD. The thinning of the macular chor-
oid may be partially involved in the development of CNV 
associated with AMD. In eyes with high myopia, previous 
reports have shown that the choroid is extremely thin;29,30 the 
central choroidal thickness in our patients with high myopia 
was 53.6 ± 38.1 µm, which was much thinner than in patients 
with AMD and PCV . In addition, Ikuno et al31 reported that 
eyes with myopic CNV have a thinner choroid than their 
contralateral eye without CNV; the authors speculated that 
a thinner choroid is a risk factor for CNV in eyes with high 
myopia.23,24,31
Treatment with ranibizumab is expected to induce long-
term inhibition of all isoforms of VEGF-A in the eye.1 It 
may well be that physicians are concerned about the adverse 
effect of ranibizumab on the choroid, especially when they 
treat eyes with AMD or high myopia. In the current study, 
choroidal thickness (167.2 ± 108.3 µm) showed no signifi-
cant change after the loading phase (165.2 ± 107.8 µm) or at 
final examination (164.8 ± 107.7 µm). In a PubMed search, 
we could find no reference to changes in choroidal thickness 
after anti-VEGF treatment. Based on a   retrospective analysis 
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Recently, Maruko et al26 reported that subfoveal choroidal 
thickness is decreased after photodynamic therapy in eyes 
with PCV . In addition, the authors suggested that the choroi-
dal thickening seen in PCV eyes is associated with increased 
choroidal vascular hyperpermeability.26 After photodynamic 
therapy, choroidal thickness in eyes with PCV was reduced 
not only in the macular area, where the photodynamic therapy 
was performed, but also beyond the vascular arcade. Photo-
dynamic therapy could possibly reduce choroidal thickness 
by decreasing choroidal vascular hyperpermeability. Our 
patients with PCV showed no significant reduction in choroi-
dal thickness after ranibizumab treatments. Although VEGF 
works to increase the vascular permeability in the eye,42 the 
effect of the ranibizumab on choroidal vascular permeability 
may be limited.
Papadopoulou et al43 recently reported a reduction in the 
vessel caliber of the retinal arterioles in eyes with AMD after 
treatment with ranibizumab. In addition, other investigators 
have reported the vasoconstriction44 or even occlusion of 
retinal arterioles45,46 induced by intravitreal injections of 
bevacizumab, another anti-VEGF agent. Because VEGF 
Figure 3 Myopic choroidal neovascularization (CNV) treated with ranibizumab.
Notes: (Top left) right eye of a 67-year-old woman with CNV secondary high 
myopia. Spherical equivalent was −8.75 diopters, and axial length was 27.64 mm. 
initial visual acuity in the left eye was 0.3 in a Landolt chart (0.52 in logarithm of the 
minimal angle of resolution). (Top middle and right) Fluorescein (left) and indocyanine 
green (right) angiography shows a small CNV. (Middle) A horizontal section through 
the fovea before treatment obtained by optical coherence tomography without 
the enhanced-depth imaging technique. CNV accompanied exudative change with 
surrounding serous retinal detachment. Central retinal thickness was 479 µm and 
central choroidal thickness was 43 µm. (Bottom) A horizontal section through 
the fovea after a single injection of ranibizumab. Intraretinal fluid was absorbed 
completely  (central  retinal  thickness,  250  µm),  and  visual  acuity  improved  to 
0.7 in a Landolt chart (0.15 in logarithm of the minimal angle of resolution). The 
choroidal structure shows no changes (central choroidal thickness, 40 µm).
Abbreviation: CSi, chorioscleral interface.
Figure 1 Choroidal neovascularization (CNV) associated with age-related macular 
degeneration treated with ranibizumab.
Notes: (Top left) Left eye of an 81-year-old man with CNV associated with age-
related macular degeneration. initial visual acuity in the left eye was 0.2 in a Landolt 
chart (0.70 in logarithm of the minimal angle of resolution) and refractive error 
was −1.75 Diopter. (Top middle) Fluorescein angiography shows a minimally classic 
CNV.  (Top  right)  indocyanine  green  angiography  shows  no  polypoidal  lesions. 
(Middle) A horizontal section through the fovea obtained by optical coherence 
tomography  with  the  enhanced-depth  imaging  technique  before  the  treatment. 
Multiple cystoid spaces are seen. Central retinal thickness was 529 µm, and central 
choroidal thickness was 105 µm. (Bottom) A horizontal section through the fovea 
after three monthly injections of ranibizumab at the loading phase. intraretinal 
fluid  was  absorbed  completely  (central  retinal  thickness,  157  µm),  and  visual 
acuity improved to 0.3 in a Landolt chart (0.52 in logarithm of the minimal angle of 
resolution). The choroidal structure shows no changes (central choroidal thickness, 
101 µm). At 9 months, the central choroidal thickness was still 103 µm.
Abbreviation: CSi, chorioscleral interface.
Figure 2 Polypoidal choroidal vasculopathy treated with ranibizumab.
Notes:  (Top  left)  Left  eye  of  a  58-year-old  man  with  polypoidal  choroidal 
vasculopathy. initial visual acuity in the left eye was 0.15 in a Landolt chart (0.82 in 
logarithm of the minimal angle of resolution). (Top middle) Fluorescein angiography 
shows occult with no classic choroidal neovascularization. (Top right) indocyanine 
green angiography shows a branching vascular network terminating in polypoidal 
lesions.  (Middle)  A  horizontal  section  through  the  fovea  obtained  by  optical 
coherence  tomography  using  the  enhanced-depth  imaging  technique  before  the 
treatment  shows  fibrin  exudates  with  surrounding  serous  retinal  detachment. 
Central retinal thickness was 295 µm and central choroidal thickness was 270 µm. 
(Bottom) A horizontal section through the fovea after three monthly injections 
and an additional injection of ranibizumab. Exudative change was almost absorbed 
(central retinal thickness, 235 µm), and visual acuity improved to 0.6 in a Landolt 
chart (0.22 in logarithm of the minimal angle of resolution). The choroidal structure 
showed no changes, and the central choroidal thickness was 259 µm.
Abbreviation: CSi, chorioscleral interface.
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we studied only the change in the thickness of the choroid 
and did not evaluate changes in its function. It is possible that 
choroidal blood flow changes with ranibizumab treatment. 
Therefore, it may be necessary to evaluate choroid function 
during ranibizumab treatment as well.
Acknowledgements
This study was supported in part by the Japan Society for the 
Promotion of Science (JSPS), Tokyo, Japan (Grant-in-Aid for 
Scientific Research, no 21592256), and by the Japan National 
Society for the Prevention of Blindness, Tokyo, Japan.
Contributions of the authors were as follows:   Conception 
and design of the study (AAE, AT, NY); analysis and 
  interpretation (AAE, AT, KO, SO, KY, AO, NY); writing 
of the article (AAE, AT); critical revision of the article 
(KO, SO, KY, AO, NY); final approval of the article (AAE, 
AT, KO, SO, KY, AO, NY); and data collection (AAE, AT, 
KO, SO, KY, AO).
The Institutional Review Board and Ethics Committee 
of Kyoto University approved this study, which adhered 
to the tenets of the Declaration of Helsinki. Written 
informed consent was obtained from each subject before 
examination.
Age related macular degeneration Polypoidal choroidal vasculopathy
Myopic CNV

















































































Figure 4 Changes in mean central retinal thickness and mean central choroidal thickness during ranibizumab treatment for choroidal neovascularization (CNV) in eyes with 
age-related macular degeneration (top left), polypoidal choroidal vasculopathy (top right), and myopic CNV (second row).
Notes: The black squares indicate central retinal thickness; the open circles indicate central choroidal thickness. *P , 0.01, compared with values before treatment. At the 
loading phase, all eyes with PCV and AMD received three successive intravitreal injections of ranibizumab at monthly intervals (at baseline and at 1 and 2 months); eyes with 
myopic CNV were treated by a single injection of ranibizumab.
is reported to induce vascular dilation and increase retinal 
blood flow,12 pan-inhibition of VEGF by ranibizumab may 
cause vasoconstriction of retinal arterioles. However, we 
found no prominent effects of ranibizumab on choroidal 
thickness; it is unclear why no effects were seen. One 
possibility is that the concentration of ranibizumab in the 
choroid is low due to the blockage of the retinal pigment 
epithelium. Another possibility is that VEGF has a limited 
role in the control of blood flow and vascular permeability 
in the choroid.
Major limitations of the current study are its small sample 
size, lack of controls, and short follow-up period. Another 
limitation is that measurement of choroidal thickness was 
performed manually and only at the fovea. The measure-
ment of choroidal thickness tends to be affected by focal 
irregularity or indistinctness of the chorioscleral border.23,24,40 
The raster scan protocol, which uses many measurement 
points from an OCT at a longer wavelength, would minimize 
measurement errors. Software to determine the borders of 
the choroid automatically is essential to standardize this 
technique further.41,47,48 Despite these shortcomings, our 
findings suggest that the effect of ranibizumab on choroidal 
thickness can be estimated to be minimal, if any. However, 
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